News | July 09, 2021
Pfizer and BioNTech expects third dose clinical studies of COVID-19 vaccine in August
The companies anticipate clinical studies to begin in August, subject to regulatory approvals
The companies anticipate clinical studies to begin in August, subject to regulatory approvals
In addition to supporting the ongoing development of the first IND-approved product in clinical trials, the proceeds will also be used to expand the 3D printed drug product pipeline
ZyCoV-D had already exhibited a robust immunogenicity and tolerability and safety profile in the adaptive Phase I/II clinical trials
The expanded laboratories and manufacturing facilities at Nansha are expected to come online between Q1 2022 and Q3 2022
The TWYMEEG approval is supported by numerous preclinical and clinical studies, including the Phase 3 TIMES (Trials of IMeglimin for Efficacy and Safety) program managed jointly by both the companies
This will enable Mangalam to reduce its reliability on Chinese imports for this product and also help to maintain an uninterrupted supply chain to a great extent
The company expects to see steady performance led by new launches and gradual normalization post the scale-up in vaccination
These vaccine doses will be manufactured and stockpiled by the company from August-December 2021
Cadila's ZyCov-D (DNA-based vaccine) is undergoing phase III trials.
Mucormycosis drug AmphoTLC will be imported from Taiwan by Stelis Biopharma Private Limited (Stelis), the biotech arm of Strides group, and will be launched and distributed in India immediately by Strides
Subscribe To Our Newsletter & Stay Updated
